A Randomized, Single-Dose, Placebo-Controlled, Study of the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid Arthritis
Phase of Trial: Phase I
Latest Information Update: 23 Aug 2016
At a glance
- Drugs AMP 110 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; First in man
- Sponsors Amplimmune; MedImmune
- 12 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Dec 2013 Planned End Date changed from 1 Nov 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 09 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.